UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

~~FORM~~Form 8-K

~~CURRENT~~Current ~~REPORT~~Report

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of ~~report~~ Report (~~date~~Date of earliest event reported): ~~August~~February 104, ~~2007~~ 2010

Worldwide Biotech and Pharmaceutical Company

(Exact name of ~~small~~registrant ~~business issuer~~ as specified in its charter)

Delaware	01-06914	59-0950777
Delaware (State or other jurisdiction of incorporation)	01-06914 (Commission File Number)	59-0950777 (I.R.S. Employer Identification No.)
(State or other jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)
4 Fenghui South Road, Jie Zuo Mansion, 15th Floor, A10-11501 Xi’an, Shaanxi, P. R. China, 710075 (Address of principal executive offices) (zip code)
86-29-88193339 (Registrant’s telephone number, including area code)
	________________________________________________
(Former name or former address, if changed since last report.)

4 Fenghui South Road, Jie Zuo Mansion, 15th Floor, A10-11501,

Xi’an, Shaanxi, P.R. China, 710075

(Address of principal executive offices)

86-29-88193339

(Registrant telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

-Item 4.01 Changes in ~~1 -~~Registrant’s Certifying Accountant.

~~Section~~On February 4:, ~~Matters~~2010, ~~Related~~Worldwide toBiotech and Pharmaceutical Company (the “Registrant”) dismissed Kempisty & Company, Certified Public Accountants, P.C. ~~and~~(“Kempisty ~~Financial~~& ~~Statements~~Company”) as the Registrant’s independent registered public accounting firm.

~~Item~~For the 4year ended December 31, 2008, Kempisty & Company issued an audit report on the Registrant’s consolidated balance sheet as of December 31, 2008, and the related consolidated statements of operations, stockholders’ equity (deficit) and comprehensive income (loss), and cash flows for the year then ended.~~01.~~ ~~Changes~~The report inof Kempsity & Company on the foregoing financial statements did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to any uncertainty, audit scope or accounting principles, except for an explanatory paragraph related to the Registrant'’s ~~Certifying~~ability ~~Accountant~~to continue as a going concern.

~~(a)~~In ~~On August 8~~addition, ~~2007,~~Kempisty ~~the~~& ~~Registrant dismissed Zhong Yi (Hong Kong) C.P.A.~~ Company ~~Limited~~ ~~(“Zhong~~reviewed ~~Yi”)~~management’s asprepared ~~its independent certifying accountant. Zhong Yi had been the independent registered public accounting firm for and audited the~~ consolidated financial statements offor the Registrant ~~as of December 31, 2006 and interim reports through the company last 10-QSB~~ for the ~~period~~quarters ~~ending~~ended March 31, ~~2007.~~ ~~The reports of Zhong Yi on the consolidated financial statements of the Registrant for the past fiscal year contained no adverse opinion or disclaimer of opinion~~2009, ~~and were not qualified or modified as to uncertainty, audit scope~~ ~~or accounting~~June ~~principles~~30, ~~except~~2009 ~~for~~and anSeptember explanatory paragraph relating to the Registrant ability to continue as a "going concern." The decision to change accountants was approved by the Board of Directors of the Registrant on August 830, ~~2007~~2009.

InDuring ~~connection with~~ the ~~audits~~year ~~for~~ended ~~the~~December ~~most~~31, ~~recent~~2008 ~~fiscal years~~ and inall ~~connection with Zhong Yi review of the~~ subsequent interim periods ~~through~~and ~~the date of~~through ~~dismissal~~February ~~on August 8~~4, ~~2007~~2010, (i) there ~~have~~were ~~been~~ no disagreements between the Registrant and Kempisty ~~Zhong~~& YiCompany on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement(s), if not resolved to the satisfaction of ~~Zhong~~Kempisty ~~Yi,~~& Company would have caused ~~Zhong~~Kempisty Yi& Company to make reference ~~thereto~~to the subject matter of disagreement in ~~their~~connection ~~report~~with its reports on the Registrant ’s financial statements, ~~for~~and ~~these~~(ii) ~~fiscal~~there ~~years~~were no reportable events as that term is described in Item 304(a)(1)(iv) of Regulation S-K.

~~The~~On ~~Registrant~~February ~~has~~4, ~~made~~2010, ~~the~~we ~~contents~~engaged ofYichien ~~this~~Yeh, ~~Form~~CPA ~~8-K~~(“Yeh”) ~~filing~~as ~~available~~the toRegistrant’s ~~Zhong~~new ~~Yi and~~independent ~~requested~~registered itpublic toaccounting ~~furnish~~firm. aThe ~~letter~~Registrant’s toBoard ~~the Securities and Exchange Commission~~of asDirectors torecommended, ~~whether~~authorized, ~~Zhong~~and Yiapproved ~~agrees~~the ordecision ~~disagrees with, or wishes~~ to ~~clarify~~dismiss ~~the~~Kempisty ~~Registrant~~& ~~expression~~Company ofas ~~its~~our ~~views.~~independent Aregistered ~~copy~~public ofaccounting ~~Zhong~~firm Yiand ~~letter~~ to ~~the Commission~~engage isYeh ~~included~~to serve as anour ~~exhibit~~independent toregistered ~~this~~public ~~filing~~accounting firm.

~~(b)~~ On ~~August~~February 826, ~~2007~~2010, ~~the~~we ~~Company~~provided ~~engaged~~Kempisty Li & Company, PCwith ofa ~~194~~copy ~~Tamarack~~of ~~Circle,~~this Form ~~Skillman~~8-K, NJand ~~08558,~~requested ~~USA~~that toKempisty ~~review~~& ~~the~~Company ~~consolidated~~furnish ~~balance~~us ~~sheet~~with asa ~~of June~~letter ~~30, 2007~~addressed ~~and~~to the ~~related~~Securities ~~consolidated statements of operations~~ and ~~comprehensive income,~~Exchange ~~stockholders~~Commission ~~equity,~~stating ~~and~~whether ~~cash~~or ~~flows~~not ~~(financial~~it agrees ~~statements)~~with ~~for~~ the ~~period~~ ~~then~~above ~~ended.~~statements Liwithin &ten ~~Company,~~(10) PCbusiness ~~will~~days ~~also~~of ~~review~~ the ~~Company’s~~filing ~~quarterly~~of ~~financial~~this ~~information~~Form ~~for the third quarter ending September 2007~~8-K. ~~The~~We ~~Company has~~will ~~not~~file ~~consulted~~an ~~with~~amendment Lito &this ~~Company,~~Form PC8-K ~~regarding~~within ~~the~~two ~~application~~days of ~~accounting~~receipt ~~principles to any contemplated or completed transactions nor the type~~ of ~~audit~~Kempisty ~~opinion~~& ~~that might be rendered on the~~ Company’s ~~financial~~letter ~~statements,~~ and ~~neither~~attach ~~written~~it ~~or oral advice was provided that would be an important factor considered by the Company in reaching a decision~~ as to an ~~accounting,~~ ~~auditing or financial reporting issues~~exhibit.

-Item 25.02 Departure of Directors or Certain Officers; Election of Directors; -Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

~~Section~~ On 9:February 22, 2010, Ms. Huimin Zhang resigned from her position as a Director on the Board of the Registrant and Mr. Xiaohong Bai resigned from his position as the Vice President of Operations of Yangling Daiying Biotech & Pharmaceutical Group Co., Ltd., one of the subsidiaries of the Registrant (“Yangling Daiying”). On February 23, 2010, Mr. Peiyi Tian resigned his positions as the Senior Vice President, Chief Financial ~~Statements~~Officer, Treasurer and ~~Exhibits~~Director of the Registrant. All of the aforementioned director and officers resigned for personal reasons, without any disagreements with the Registrant, and their resignations were not related to the Registrant’s operations, policies or practices. On February 24, 2010, the Board of Directors of the Registrant accepted the resignations of the Ms. Zhang, Mr. Bai and Mr. Tian.

~~Item~~On 9February 24, 2010, the Board of Directors of the Registrant elected Mr.01 Qiang Li and Mr. ~~Financial~~Peng ~~Statements~~Wang as Directors to replace Ms. Huiming Zhang and ~~Exhibits~~Mr. Peiyi Tian.

~~(c)~~In ~~Exhibits~~addition, on February 24, 2010, the Board of Directors of the Registrant appointed Mr. Peng Wang to succeed Mr. Peiyi Tian as the Chief Financial Officer and Treasurer and appointed Mr. Yuan Cheng to replace Mr. Xiaohong Bai as Vice President of Operations of Yangling Daiying.

Exhibit No.		Description
16.1		Letter of Zhong Yi (Hong Kong) C.P.A. Company Limited, dated August 8, 2007 to the Securities and Exchange Commission

Mr. Qiang Li, age 34, the Registrant’s newly-elected director, has 14 years of experience working extensively in medicine and publishing. For the two years immediately following Mr. Li’s graduation from Ruicang Health School of Jiangxi Province in 1994, he worked in Medicare services in the Nancang Taohua Hospital in Jiangxi Province. From 1996 to 2004, Mr. Li was the chief editor at the Guangdong Branch of the Xinhua News Agency. Since 2004, Mr. Li has been working for Shaanxi Daiying Medicine Distribution Co., Ltd., a subsidiary of the Registrant.

~~SIGNATURE~~Mr. Peng Wang, age 51, a graduate from Xi’an University of Finance and Economics, has worked for over 23 years in finance as a Certified Public Accountant. Prior to Mr. Wang’s appointment as the Registrant’s Chief Financial Officer and Treasurer, he served as a financial officer in governmental organizations from 1977 to 1995 and as the Chief Financial Officer of Shaanxi Yuqi Functional Product Factory from 1995 to 2000.

~~Pursuant~~Mr. Yuan Cheng, age 38, graduated in 1993 from Xi’An toMedical ~~the~~College ~~requirements~~with ofa Bachelors Degree in pharmacy. Following his graduation through 1996, Mr. Cheng worked in the ~~Securities~~quality ~~Exchange~~control ~~Act~~department of Xi’An ~~1934~~Medical Company. From 1996 to 2002, Mr. Cheng was the ~~registrant~~head of ~~has~~the production and research and development departments of Nanjing Meirui ~~duly~~Pharmaceutical ~~caused~~Co., ~~this~~Ltd. Mr. ~~report~~Cheng attended Tianjin University from 2002 to be2006, ~~signed~~where he was awarded a Masters Degree in pharmaceutical engineering. After receiving his Masters Degree, Mr. Cheng worked Shaanxi Haoqijun Pharmaecutical Co., Ltd. until his appointment on ~~its~~February ~~behalf~~24, 2010 byas ~~the~~Vice ~~undersigned~~President ~~hereunto~~of Operations of Yangling Daiying Biotech & ~~duly~~Pharmaceutial ~~authorized~~Group Co., Ltd., one of the Registrant’s subsidiaries.

	Worldwide Biotech and Pharmaceutical Company
	(Registrant)
Date: August 10, 2007	By: /s/ Wenxia Guo
	Wenxia Guo
	President and Chief Executive Officer

~~- 3 -~~SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 26, 2010	Worldwide Biotech and Pharmaceutical Company


	/s/ Wenxia Guo
	Wenxia Guo
	President and Chief Executive Officer

Filing Compare · Worldwide Biotech & Pharmaceutical CO